ArriVent BioPharma's furmonertinib demonstrates robust efficacy, CNS penetration, and tolerability in early trials. Read why ...
Tanning bed usage was associated with an increased risk of melanoma, at an odds ratio of 2.85, while further analysis revealed a dose–response relationship between the number of tanning bed exposures ...
On August 8, 2025, the FDA granted accelerated approval to zongertinib for adult patients with unresectable or metastatic ...
SurvivorNet on MSN
The evERA Trial: A Promising Treatment Option For Patients With Estrogen Receptor-Positive (ER+), HER2-Negative (HER2-) Breast Cancer
The evERA breast cancer trial marks a turning point for some patients with a specific type of advanced breast cancer known as ...
NDA submissions for bezuclastinib in Gastrointestinal Stromal Tumors (GIST) and Advanced Systemic Mastocytosis (AdvSM) are on-track for the first half of 2026 based on the strength of clinical results ...
Our top 5 highlights from the 2025 San Antonio Breast Cancer Symposium (SABCS) include articles and interviews introducing ...
Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) is one of the AI stocks under $20 to buy now. On December 8, Recursion ...
Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the most active US stocks to buy according to analysts.
The numbers are especially grim in the Big Apple: According to preliminary hospital data collected by New York City’s ...
The analysis revealed that about 2 per cent of sperm from men in their early 30s contained disease-causing mutations. That ...
Advancements in understanding tumor biology, identifying predictive biomarkers, and developing targeted therapies have ...
Efficacy and safety results of TQB2930, a HER2-targeted bispecific antibody combined with chemotherapy in patients with HER2-positive breast cancer (BC) previously treated with ≥2 line treatments: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback